蒂博隆和乳腺癌的研究
Jae Kyung Lee1,2, Hyewon Yun1,2, Heeyon Kim1,2
1Departments of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Journal of menopausal medicine
|January 17, 2024
概括
选择性雌激素活性调节剂蒂博没有显示乳腺癌风险增加. 本综述侧重于最近的研究,特别是在亚洲人群中,关于tibolone和乳腺健康.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 蒂博隆是一种合成类固醇选择性雌激素活性调节剂.
- 与传统疗法不同,提博具有组织特异性作用,激活大脑,阴道和骨中的雌激素活性.
- 蒂博隆在子宫内膜和乳腺中不活跃,促使对其乳腺癌风险进行调查.
研究的目的:
- 为了确定tibolone对乳腺组织的影响.
- 调查tibolone使用与乳腺癌风险之间的关系.
- 专注于最近的研究,特别是涉及亚洲人口的研究.
主要方法:
- 对最近的科学文献进行审查.
- 分析研究研究的分析,调查tibolone对乳腺健康的影响.
- 强调来自亚洲人口的流行病学数据.
主要成果:
- 蒂博隆似乎不会增加患乳腺癌的风险.
- 雌激素活性是局部的,节省乳腺组织.
- 最近的研究,包括亚洲研究,支持中立或潜在的保护作用.
结论:
- 提博是一种安全的更年期激素治疗选择,涉及乳腺癌风险.
- 选择性组织雌激素活性调节提供了没有典型风险的好处.
- 需要对不同种群进行进一步的研究,但目前的证据令人放心.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K


